findmyKOL
Clinical trialNCT04471415TerminatedPhase 1/PHASE2Interventional

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

SponsorDracen Pharmaceuticals, Inc.Enrollment61Advanced Solid TumorNon Small Cell Lung Cancer Metastatic
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Germany
  • Centrum Fur Integrieerte Onkologie

    Cologne, Germany

  • University Cancer Center Nct

    Dresden, Germany

  • University Hospital Frankfurt

    Frankfurt, Germany

  • University Klinikum Wuerzburg

    Würzburg, Germany

Singapore
  • National Cancer Center Singapore

    Singapore, Singapore

Spain
  • Hospital University Vall D'Hebron

    Barcelona, Spain

  • University Hospital 12 de Octubre

    Madrid, Spain

Taiwan
  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

United States
  • Honorhealth

    Scottsdale, Arizona, United States

  • Ucla

    Los Angeles, California, United States

  • Adventhealth Medical Group

    Kissimmee, Florida, United States

  • Florida Cancer Specialist

    Orlando, Florida, United States

  • Johns Hopkins Kimmel Institute

    Baltimore, Maryland, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, United States

  • Nyu Langone

    New York, New York, United States

  • University of North Carolina

    Chapel Hill, North Carolina, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, United States

  • Next Oncology

    Fairfax, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 2020
Primary completion
28 Mar 2023
Completion
28 Mar 2023
Last update posted
12 Jun 2023
Registered enrollment
61
Registry id
NCT04471415

Cross-registrations

EU-CTR / CTIS (EudraCT)2020-002770-27

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.